Purpose: Studies on the efficacy of infliximab (IFX) in a large population of pediatric patients with Crohn’s disease (CD) are limited, and prognostic factors are not well-known. The aim of this study was to evaluate outcomes of IFX in pediatric patients with CD and to identify factors associated with poor prognosis. Methods: We retrospectively analyzed medical data of 594 pediatric patients with CD between 1987 and 2013 in Seoul Asan Medical Center. Of these, 156 children treated with IFX were enrolled and were followed up for at least a year with intact data. Outcomes of induction and maintenance, classified as failure or clinical response, were evaluated at the 10th and 54th week of IFX therapy. Results: We treated 156 pediatric CD patients with CD with IFX, and the median duration of IFX therapy was 47 months. For IFX induction therapy, 134 (85.8%) patients experienced clinical response at the 10th week. Among the 134 patients who showed response to induction, 111 (82.8%) patients maintained the clinical response at the 54th week. In multivariate analysis, low hematocrit ( P = 0.027) at the time of IFX initiation was associated with the failure of IFX induction. For IFX maintenance therapy, longer durations from the initial diagnosis to IFX therapy ( P = 0.017) were associated with maintenance failure at the 54th week. Conclusion: Measures of clinical severity, such as hematocrit, were related to the response of IFX induction in children with CD. Early administration of IFX showed better outcomes in IFX maintenance therapy.